The PPAR α Pocket: Renewed Opportunities for Drug Development

Åsmund Kaupang and Trond Vidar Hansen

Section for Pharmaceutical Chemistry, Department of Pharmacy, University of Oslo, 0316 Oslo, Norway

Correspondence should be addressed to Åsmund Kaupang; asmund.kaupang@farmasi.uio.no

Received 29 January 2020; Accepted 13 May 2020; Published 1 July 2020

Guest Editor: Hongbao Cao

Copyright © 2020 Åsmund Kaupang and Trond Vidar Hansen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The past decade of PPARγ research has dramatically improved our understanding of the structural and mechanistic bases for the diverging physiological effects of different classes of PPARγ ligands. The discoveries that lie at the heart of these developments have enabled the design of a new class of PPARγ ligands, capable of isolating central therapeutic effects of PPARγ modulation, while displaying markedly lower toxicities than previous generations of PPARγ ligands. This review examines the emerging framework around the design of these ligands and seeks to unite its principles with the development of new classes of ligands for PPARα and PPARβ/δ. The focus is on the relationships between the binding modes of ligands, their influence on PPAR posttranslational modifications, and gene expression patterns. Specifically, we encourage the design and study of ligands that primarily bind to the Ω pockets of PPARα and PPARβ/δ. In support of this development, we highlight already reported ligands that if studied in the context of this new framework may further our understanding of the gene programs regulated by PPARα and PPARβ/δ. Moreover, recently developed pharmacological tools that can be utilized in the search for ligands with new binding modes are also presented.

1. Introduction

The peroxisome proliferator-activated receptors (PPARs) are members of a class of transcription factors whose regulation of gene transcription is modulated by ligand binding—a class also known as nuclear receptors. The three PPAR subtypes described thus far, PPARα, PPARβ/δ, and PPARγ (NR1C1, NR1C2, and NR1C3, respectively) [1], are multidomain proteins that each consist of a highly mobile N-terminal domain (domains A/B), a DNA-binding domain (DBD, domain C), a hinge region (domain D), and a C-terminal ligand-binding domain (LBD, domains E/F). Of these, the N-terminal and the C-terminal domains, respectively, contain the ligand-independent activation function 1 (AF-1) and ligand-dependent activation function 2 (AF-2) (Figure 1(a)) [2, 3]. The PPARs are primarily described as acting through heterodimeric complexes with the retinoic X receptors (RXRs) [4]. Upon binding to DNA, each DBD of the PPAR:RXR heterodimer typically interacts with its own half-site of a peroxisome proliferator response element (PPRE) in the promoter or enhancer region of a target gene, e.g., a repeated consensus sequence separated by a single nucleotide—a direct repeat 1 (DR1) element (Figure 1(b)) [5–7]. The PPAR:RXR heterodimer is characterized as permissive, in the sense that the binding of ligands in the ligand-binding pocket (LBP) of either receptor can activate transcription. Thus, while the binding of 9-cis-retinoic acid (Figure S1) or other RXR agonists to the RXR LBP can positively regulate target genes, the binding of an agonist to the PPAR LBP appears to exert a stronger and dominant role in the activation of the PPAR:RXR heterodimer. Coherently, the binding of agonists to both receptors can synergistically activate transcription [8–11].

In the canonical mechanism, the introduction of an agonist in the PPAR LBP leads to the release of a corepressor protein complex bound to the apo-PPAR:RXR heterodimer through platform proteins such as nuclear receptor corepressor (NCoR), silencing mediator for retinoid and thyroid
hormone receptors (SMRT) or SMRT and histone deacetylase-associated protein (SHARP), that either contain or interact with histone deacetylases (HDACs) [15–18]. The holo-PPAR-RXR complex subsequently recruits coactivator proteins such as CREB-binding protein (CBP), steroid receptor coactivator 1–3 (SRC1–3), mediator complex subunit 1 (MED1, TRAP220, or DRIP205), or PPARy coactivator 1α (PGC-1α), which in turn recruit other nuclear proteins leading to a coactivator complex that usually displays histone acetylase (HAT) activity. The switch from the action of HDACs to that of HATs increases histone acetylation and leads to the remodelling of chromatin required for the assembly of the functional, multiprotein transcription complex [19–22]. Subsequent transcription of PPAR target genes completes the process known as transactivation. Interestingly, the binding of a PPAR agonist can also lead to the recruitment of certain corepressor proteins, such as receptor-interacting protein 140 (RIP140) [23, 24] or TNFαIP3-interacting protein 1 (TNIP1) [25], that contain receptor-interacting domains (RIDs) similar to those found in coactivator proteins [26].

In contrast to the PPRE-mediated regulation of target gene expression by the PPAR/RXR heterodimer, a holo-PPAR monomer can also interact directly with other transcription factors and attenuate the expression of their target genes—a mechanism called transrepression [27–33]. This fundamentally different mechanism of transcriptional regulation has been shown to be involved in, e.g., the anti-inflammatory effects of PPAR activation [31, 32, 34–36].

The proteins produced upon the expression of PPAR target genes hold key roles in the regulation of lipid and glucose metabolism [37–39]. Consequently, the PPARs have attracted significant attention as possible points of pharmacological intervention in human metabolic diseases. Through the last decades, several members of classical agonist families such as the fibrates (PPARα), the glitazones (PPARγ), and the glitazars (PPARα/γ) have been approved for the treatment of metabolic diseases in humans. However, many of these drugs have since been withdrawn from the market due to the serious side effects that accompanied their clinical use (e.g., carcinogenesis in various tissues, myocardial infarction, loss of bone density, and weight gain) [40–51]. Albeit efficacious at improving selected metabolic parameters in patients, the relative failure of PPAR classical agonists to represent safe treatment options may have caused researchers both in academia and in the industry to abandon further ligand development targeting the PPARs.

Nevertheless, results from the last decade, particularly from the study of the effects of partial and nonagonistic ligands on PPARγ, suggest that the side effects caused by classical agonists and some of the desired, beneficial effects of PPARγ ligation are of separate mechanistic origins. Together, these results form a basis for a new ligand design paradigm, a key concept of which relates to how ligand binding can modulate the occurrence of posttranslational modifications (PTMs) of PPARγ, which in turn lead to particular patterns of gene expression. This and related concepts from the history of PPARγ ligand development are reviewed initially. We then venture to apply these concepts to historic and future ligand development in PPARα and PPARβ/δ by highlighting results and ligands that merit renewed attention and further study as
tools that can potentially reveal hereto unknown transcriptional profiles of therapeutic relevance.

2. PPAR Structure

In addition to the large body of atomic resolution data existing in the public domain on the structures of both apo- and holo forms of the LBDs of the PPARs (domains E/F), our understanding of the structures of the C and D domains, as well as the quaternary organization of domains C–F, is improving [7, 12, 52, 53]. Less is however known about the structural dispositions of the highly mobile N-terminal A/B domains and the AF-1 [54]. Nonetheless, the ability of the AF-1 to induce transcription independently of the AF-2 and of ligand binding has been demonstrated [55–57]. The sequences of the A/B domains also vary significantly between the PPAR subtypes and between the observed splice variants (isoforms) of each subtype [58–61].

The structure of the PPAR LBD comprises a sandwich of helices 1–12 (H1–H12), 3–4 β strands (β1–β4), and several prominent loops, with the overall fold being similar to that of other nuclear receptors (NRs) in the steroid hormone receptor superfamily. For the standard PPAR helix numbering scheme, see Uppenberg et al. [63]. The main cavity of the LBD is larger than in other NRs (~1300 Å³ [64, 65]) and wraps around the central H3. On either side of H3, the cavity is capped either by the Ω loop (the H2′-H3 loop) or by the H12 and the H11–H12 loop. The subcavities on either side of H3 extend along its axis and are additionally limited by the H1–H2 loop, the β sheet region, H2′, H5, and H6, on the one side, and by H5, H7, and H11, on the other side. Taking cues from the nomenclature employed by Waku et al. [66], these two subcavities of the PPAR LBP will be referred to as the Ω pocket and the AF-2 pocket, respectively (Figure 2). Comparing with more recent literature on PPARγ, these cavities roughly align with the regions referred to as the alternate- or allosteric binding site and the orthosteric binding site, respectively [67, 68]. Overall, the LBPs of the PPARs can be regarded as T- or Y-shaped and they have reactivity of which have not been established (Figure 2).

3. Classical PPAR Agonism, Antagonism, and beyond

Structurally, the dissociation of a corepressor protein complex and association with a coactivator protein complex appears to be related to the formation of a tighter groove between H3, H4, and H12, suited for the binding of the RIDs of a given coactivator protein, but that is unable to accommodate the slightly longer RIDs of typical corepressor proteins [64, 85–88]. As the outer surface of H12 is central to the binding of coactivator proteins, many of the known PPAR ligands have either been observed to, or have indeed been designed to, stabilize H12 through interactions with a conserved hydrogen bonding network in the AF-2 pocket, involving conserved tyrosine and histidine residues on H5, H11, and H12 [89].

Access to the AF-2 pocket through the binding of the head groups of classical agonistic ligands has also opened for the development of ligands that display H12-mediated antagonism [90]. These ligands destabilize H12 through perturbation of the AF-2 pocket hydrogen bonding network or by introducing sterically demanding moieties in the AF-2 pocket [86, 90–96]. In PPARγ, interactions with other nearby residues, such as Phe310(282) and Phe391(363), have also been implicated in the mode of action of this class of antagonistic ligands [97, 98]. Based on the observed conformations and folding states of H12 in the few available X-ray crystallographic structures of complexes with such ligands, they appear to disrupt the stable docking of H12 onto the core of the LBD and thus the formation or stabilization of the coactivator-binding groove [85, 88, 99]. In the Phe310/Phe391-interacting class of PPARγ antagonistic ligands, more subtle interactions or alternative binding modes may be involved, which in turn affect the conformational populations of H12 [97, 98].

Some of the reported antagonistic ligands display inverse agonism in that they cause the PPAR-mediated transcription to fall below basal levels in a given model system or assay [91, 94, 95, 97, 103]. In similarity to other reported PPAR inverse agonists [104–106], the observed subbasal transcription levels are likely reflected in the tendency of such ligands to strengthen the interactions of the PPARs with corepressor proteins, such as NCoR and SMRT, compared to those of the apo-PPARs [85, 88, 93, 103–106].

Considering LBD conformational dynamics, ligand binding leads to changes in the conformational populations of the LBD, as observed by nuclear magnetic resonance (NMR) spectroscopy [68, 86, 87, 97, 107–111], hydrogen–deuterium exchange coupled to mass spectrometry (HDX-MS) [68, 97,
and molecular dynamics (MD) simulations [86, 87, 96, 118, 119]. In PPARγ, analyses of such structural ensembles have demonstrated that the large conformational diversity observed in apo-PPARγ, in particular that of H12, is strongly reduced upon interaction with classical agonists. In contrast, upon treatment with less potent agonists, partial- and nonagonists, H12 still populates several minima [87, 107]. Coherently, high H-D exchange

Figure 2: An overview of the shapes of the PPARα (a), PPARβ/δ (b), and PPARγ (c, d) LBPs and the subcavities referred to as the AF-2 pocket (light blue) and the Ω pocket (beige), lined by helix 12 (orange) and β1–β4 (yellow), respectively. For clarity, the N-terminal half of H3 and the Ω loop are hidden in the front views (top). Also, the visualizations of the LBDs have been truncated (black lines) in order to maximize the visibility of the LBP. Similarly, H2′, the Ω loop, and the N-terminal half of H3 are hidden in the top view (bottom). The sulfur atoms of the centrally located cysteines are shown as gold spheres, at 50% of their van der Waals radii. (a–c) PPARα, PPARβ/δ, and PPARγ in their respective complexes with indeglitazar (Figure S1) predominantly bound to the AF-2 pocket (PDB ID: 3ET1, 3ET2, and 3ET3, respectively) [100]. (d) PPARγ in complex with SR1664 (Figure S1) bound to the Ω pocket (PDB ID: 5DWL) [101]. The LBP surfaces were mapped with a 1.4 Å probe using HOLLOW [102], and the resulting population of probes was truncated at the solvent interface of the Ω pocket. The structures and surfaces were visualized in PyMOL (ver. 1.8.4.0) [13, 14].
rates have been observed for H12 in PPARγ treated with an inverse agonist, compared to those of H12 in apo-PPARγ [97]. Notably, the motions of the Ω loop in holo-PPAR complexes have also been suggested to affect the conformational populations of H12 [78, 118, 119].

During the last decade, evidence has accumulated on the toxicity of clinically employed PPARα and PPARγ classical agonists, such as certain fibrates [40, 41], glitazones [42–46], and glitazones [47–51], as well as that of a PPARβ/δ classical agonist in rodents [120, 121]. Combined with the knowledge of their common capacity for stabilization of H12, the frequently observed undesirable effects of these ligands could be interpreted as signs of a mechanism-based toxicity. Furthermore, as findings from the study of PPARγ demonstrate that classical agonism is not required to attain therapeutically relevant transcriptional outcomes (see Section 5), recent ligand development targeting PPARγ has aimed at avoiding ligands that strongly stabilize H12 [97, 122–127]. And while such nonclassical ligands for PPARγ are becoming numerous (Section 5.3), there is a scarcity of similar ligands for PPARα and PPARβ/δ (see Sections 6.1 and 7.1).

To amend this, the accumulated experience with the functional effects of ligand interaction with H12, delineated above, may serve as a guide for the future design of partial- and nonagonistic PPAR ligands. Ideally, these ligands should not cause a supraphysiological stabilization of H12, but may rather seek to achieve therapeutically relevant effects, e.g., by influencing PPAR posttranslational modifications (PTMs) (Section 4).

4. PPAR Posttranslational Modifications

Ligand binding is far from the only event that affects the activity and physiological roles of the PPARs during their lifetime. The PPARs are observed to be subject to a number of covalent modifications that are common to the nuclear environment and that, as such, are also found on other transcription factors and on histone proteins [128, 129]. So far, the PTMs observed in the PPARs include O-phosphorylation, O-GlcNAcylation, N-acetylation, N-SUMOylation, and N-ubiquitination [130–133]. The investigation of how each of these PTMs modulates protein function is among other things complicated by the effect one PTM can have on another. This encompasses the possibility of a direct competition between PTMs like O-phosphorylation and O-GlcNAcylation of the same serine, threonine, or tyrosine residue [134], as well as between PTMs such as N-acetylation, N-SUMOylation, and N-ubiquitination, which may compete for lysine residues [135–139]. PTMs can also operate in positive- or negative synergy, as in the case of phosphorylation-dependent SUMOylations [140–142] or as observed in the crosstalk between PTMs occurring on lysine or arginine residues, and the phosphorylation of near serine or threonine residues [143].

The PTMs that occur in the N-terminal domains of the PPARs can affect both their ligand-independent and their ligand-dependent regulation of gene expression [130–133]. However, while data exist on the influence of some of these PPAR PTMs on the degree of transactivation induced by ligand binding, less is known about the degree to which ligand binding affects the propensity of each of the PPARs towards undergoing such PTMs. From a medicinal chemistry perspective, this question may be of particular interest for PTMs occurring in the LBD, as the magnitude of the influence of ligand binding on the conformational populations of the LBD and thus on the propensity of the LBD to undergo a certain PTM could be larger than for distant regions, such as the N-terminal domain. On the other hand, conformational changes in the LBD may also lead to altered interdomain contacts that in turn can mask or unveil distant PTM sites. Thus, a modulation of the transcriptional outcome by PTMs that occur in the LBD may either be mediated by differential coregulator recruitment [116, 144, 145] or by altered interdomain contacts between the PPAR LBD, the PPAR:RXR DBDs [11, 146], or their N-termini. Additionally, such changes in the conformational populations of the PPARs may influence the promoter binding of PPAR:RXR-heterodimers [7, 12, 118] or the transrepressive activity of PPAR monomers [28–30].

Most of the knowledge on PPAR PTMs stems from studies of PPARγ and PPARα, while less is known about PTMs occurring in PPARβ/δ [130–132]. Interestingly, a large number of consensus PTM sites can be found in the primary sequences of all three PPARs using PTM consensus site mapping algorithms such as GPS-PAIL [147] (N-acetylation), PhosphoNET [148], PhosphoMotif Finder [149], or NetPhos [150, 151] (O-phosphorylation) (Figure 3).

Meanwhile, databases of experimental PTM data, such as PhosphoSitePlus [152], contain records of several PTMs (not limited to phosphorylation), some of which occur in the PPAR LBDs. Among these, some ligand-sensitive PTMs occurring in the PPAR LBDs have been identified and studied experimentally, such as the phosphorylation of PPARγ Ser273, the acetylation of PPARγ Lys268/Lys293, and the phosphorylation of PPARα Ser179/Ser230 (Figure 3 and Sections 5.1, 5.2, and 6, respectively). Guided by data obtained from studies of these PTMs, their therapeutic relevance and the mode of action of the ligands that influence their occurrence are discussed in the following sections.
5. New Directions in PPARγ Pharmacology Guided by Relationships between Ligand Binding and PTMs

Among the beneficial effects of PPARγ activation by classical agonists, such as the thiazolidinediones (TZDs) used in the treatment of type II diabetes mellitus (T2DM) and other morbidities associated with obesity, two important axes have been recognized: firstly, improved insulin sensitivity and glucose tolerance, and secondly, increased energy expenditure in white adipose tissue [153, 154]. While historically the structural and mechanistic bases for each of these effects have been unclear, the discoveries and studies of the PTMs introduced above have greatly improved our understanding of their separate origins.

5.1. Posttranslational Phosphorylation of Ser273(245) in the PPARγ LBD. In 2010, following the identification of a consensus site for phosphorylation by cyclin-dependent kinase 5 (Cdk5) in PPARγ, Choi et al. demonstrated that Cdk5 indeed phosphorylates Ser273 and that this PTM was associated with insulin resistance in obese mice and humans [116]. The authors could also show that tumor necrosis factor (TNFα) induced this phosphorylation, indicating a link between this PTM and the inflammatory state of the obese mice. Using a nonphosphorylatable Ser273Ala mutant, Choi et al. further demonstrated that Ser273 phosphorylation was linked to a reduction in the expression of a subset of PPARγ target genes, including genes linked to insulin sensitivity such as adipin and adiponectin [116]. The importance of this discovery was amplified by two concurrent findings: firstly, ligand binding decreased phosphorylation at Ser273 and secondly, the ability of a ligand to inhibit Ser273 phosphorylation did not correlate with its ability to induce adipogenesis or transcription in PPARγ reporter gene assays [116, 122]. These results were also in line with observations made previously by other workers, who had developed PPARγ ligands that were poor inducers of transcription of PPARγ reporter constructs, yet displayed potent insulin-sensitizing activity in isolated rodent cells and in vivo [155–161].

Choi et al. later demonstrated that a selective interaction of PPARγ phosphorylated at Ser273 (pSer273-PPARγ) with the coregulator protein thyroid hormone receptor-associated protein 3 (Thrap3) underlies the diabetogenic gene dysregulation [162]. In contrast, dephosphorylated PPARγ appears to interact with the coactivator SRC3 [116, 144]. The same group further demonstrated that in the absence of Cdk5, extracellular signal-regulated kinase (ERK) can directly phosphorylate Ser273 in PPARγ and that this phosphorylation is similarly inhibited by PPARγ ligands. In this work, Banks et al. also revealed Thr296 as a novel site of Cdk5 phosphorylation in PPARγ (Figure 3) [163].

Taken together, the above-described findings strongly suggested that an important part of the antidiabetic effects of PPARγ ligands was not linked to their potency as classical agonists but rather to their inhibition of Ser273 phosphorylation [116]. Against the background of the potentially life-threatening side effects observed in the clinical use of PPARγ classical agonists such as the glitazones [42–46], that in comparison strongly stabilize H12 [114, 115], these findings launched a new era for PPARγ-targeting pharmacotherapeutics for the treatment of metabolic disease, in which the focus has shifted towards the development of potent inhibitors of Ser273 phosphorylation, that display little or no classical agonism [123, 127, 164–166].

The discoveries described above were complimented by results from Li et al., who demonstrated that the interaction of Cdk5 with PPARγ was enhanced by interaction of PPARγ with the corepressor protein NCoR [144]. This effect was also observed in adipocyte-specific NCoR knockout mice, in that they displayed decreased levels of pSer273-PPARγ [144]. Together, these findings suggest that an inhibition of PPARγ association with NCoR may be a necessary aspect of the antidiabetic mode of action of PPARγ ligands (see also Section 5.2). Interestingly, Guo et al. recently demonstrated that for optimal repression of PPARγ, but not of PPARα and PPARβ/δ, both NCoR and SMRT make use of the corepressor complex component G protein pathway suppressor 2 (GPS-2) [167].

5.2. Posttranslational Acetylation of Lysine Residues in the PPARγ LBD. The interaction of PPARγ with NCoR has also been central to the study of another ligand-sensitive PTM, namely, the acetylation of Lys268 (Lys238, mPPARγ1) [145, 168] and Lys293 [145], which are located in the H2α loop, close to Ser273, and in the Ω loop, respectively (Figure 3). Qiang et al. demonstrated that acetylation of both these lysine residues promoted PPARγ binding to NCoR and that this interaction was further strengthened in the presence of the HAT-containing coactivator protein CBP [145]. Using Lys-Gln mutants to mimic lysine acetylation, the authors also found that the acetylation of Lys293, but that not of Lys268, was linked to Ser273 phosphorylation [145]. These results thus paralleled the previous demonstration by Li et al. of the enhanced interaction of Cdk5 with NCoR-bound PPARγ [144].

Intriguingly, treatment of PPARγ with rosiglitazone, which inhibits Ser273 phosphorylation, also leads to deacetylation of Lys268 and Lys293 (among other lysines [168]) by the nicotinamide adenine dinucleotide- (NAD+) dependent deacetylase Sirtuin 1 (SirT1) [145, 169, 170]. The SirT1-mediated deacetylation of PPARγ was first shown by Han et al., who also demonstrated that PPARγ overexpression or troglitazone (Figure S1) treatment could downregulate SirT1 through the binding of an inhibitory PPARγ/SirT1 complex on the SIRT1 promoter [171]. Nonetheless, Qiang et al. further demonstrated that the SirT1-mediated deacetylation of Lys293 in particular promoted the interaction of PPARγ with the coregulator PR domain zinc finger protein 16 (Prdm16) [145], which in turn upregulated a thermogenic, brown adipose tissue- (BAT-) related gene program in white adipose tissue (WAT) [145, 172, 173]. In further support of a link between the inhibition of phosphorylation of Ser273 and the deacetylation of Lys293, Wang et al. recently demonstrated that treatment of 3T3-L1-derived adipocytes with the Cdk-inhibitor roscovitine...
(Figure S1) promoted the dissociation of PPARγ from NCoR, its association with SirT1 and Prdm16, and the subsequent expression of BAT-related genes such as uncoupling protein 1 (UCP1) [174]. Similar results were obtained with a nonphosphorylatable PPARγ Ser273Ala mutant [174]. In contrast, Qi et al. observed that while both a Ser273Ala mutant and a nonacetylatable Lys268Arg/Lys293Arg double mutant could induce adiponectin in differentiated Swiss 3T3 cells, only the Lys268Arg/Lys293Arg double mutant caused an upregulation of Ucp1 compared to wild-type PPARγ [145]. Indeed, the interplay between PPARγ acetylation and the phosphorylation status of Ser273 appears to be complex; Mayoral et al. observed that a short-term high-fat diet (HFD) led to increased PPARγ acetylation and Ser273 phosphorylation in adipocyte-specific SirT1 knockout (ATKO) mice. However, although a chronic HFD (15 weeks) led to a further increase in PPARγ acetylation, it was accompanied by a decrease in Ser273 phosphorylation. Consistently, the ATKO mice displayed a concomitant increase in the expression of an insulin-sensitizing gene set and were thus better protected against the negative metabolic effects of the HFD, compared to wild-type mice [175].

As mentioned above, treatment of PPARγ with rosiglitazone, which binds to both the AF-2 pocket and the Ω pocket, leads to deacetylation of Lys268 and Lys293 [145, 169, 170]. However, despite the proximity of Lys268 and Lys293 to a ligand binding in the Ω pocket, Ohno et al. demonstrated that several partial and nonagonistic PPARγ ligands, which bind to the Ω pocket and inhibit Ser273 phosphorylation [116], had practically no effect on the upregulation of the brown adipocyte marker Ucp1 in mice, compared to rosiglitazone [173]. In contrast, the partial agonist telmisartan (Figure S1) [176, 177], which also inhibits Ser273 phosphorylation [178], has been shown to moderately upregulate Ucp1 [179, 180]. Additionally, although its binding mode in the PPARγ LBP is not known, the partial agonist natural product formononetin (Figure S1) [181] displayed the same ability [182]. In summary, these results indicate that the structural mechanisms through which PPARγ ligands can influence the acetylation status of Lys268/Lys293 and the upregulation of BAT-related genes in WAT, is in need of further study [183, 184].

5.3. Effects of Interaction Patterns and Binding Stoichiometries in the PPARγ LBP on Ser273 Phosphorylation and Transactivation. Given that various classical agonists, partial and nonagonists of PPARγ can all be efficacious as, e.g., insulin sensitizers, the observed toxicity of classical agonists in clinical use has emphasized a need to examine the interactions of each of these ligand classes with the PPARγ LBP, in order to establish which interaction patterns are likely to be conducive to desirable effects, such as the inhibition of Ser273 phosphorylation. In this vein, data from techniques such as X-ray crystallography and HDX-MS have demonstrated that a general theme among PPARγ ligands that are capable of inhibiting Ser273 phosphorylation is their binding to the Ω pocket, where they interact with the β-sheet region, H2, the Ω loop, or H3 [101, 114, 185]. Through analysis of the binding mode of the 2-aminopyridine tail of rosiglitazone (Figure S1) in the Ω pocket, and subsequent ligand design, Baet al. showed that interaction with a region between H3, residues 312-313 (284-285), and the β3-β4 loop, residues 368-370 (340-342), was conducive to the inhibition of Ser273 phosphorylation [101]. Notably, this region partially overlaps with the probe clusters P4 and P3, identified in a solvent mapping of the PPARγ LBP performed by Sheu et al., a study which also revealed several other possible sites of ligand interaction in the Ω pocket [186]. Consistently, a varied set of ligands of synthetic origin display the general interaction pattern outlined above and inhibit Ser273 phosphorylation, such as MRL24 [116], BVT.13 [116], nTZDpa [116], Mbx-102 [116], GQ-16 [115], F12016 [187], and imatinib [112] (Figure S1). Additionally, a range of natural products of diverse origins [188] bind to the PPARγ Ω pocket, some of which have been demonstrated to inhibit Ser273 phosphorylation, e.g., ionomycin [189], pseudoginsenoside F11 [190], amorfrutin 1 [191], and cherlerythrine [192] (Figure S1).

The design of ligands for PPARγ Ω pocket is complicated among other things by the potential of the PPARγ LBP to harbour more than one ligand simultaneously. Thus, although the binding of a single ligand to the PPARγ Ω pocket was observed crystallographically already in the early days of PPAR research [193], multiple ligands have since been observed to occupy the LBP in complexes with ligand: receptor stoichiometries of 2:1 [10, 66, 80, 194–198] and 3:1 [66, 199]. Additionally, Shang et al. recently identified electron densities in data from PPARγ cocrystals previously thought to be stoichiometric complexes, corresponding to cocrystallized nonanoic acid ligands [200]. Such passenger fatty acids, likely derived from the bacteria in which the PPAR proteins are expressed, have also been observed in PPARβ/δ cocrystals [201, 202].

As metabolic sensors, the PPARs are moderately to strongly activated by medium chain fatty acids (MCFAs) [199, 203], long-chain mono- and polyunsaturated fatty acids (MUFAs/PUFAs) and some of their metabolites [65, 204–209], as well as by oxo- and nitro-fatty acids [76–78, 80–82]. The members of the latter two ligand groups bind covalently to the central cysteine residue, Cys313(285) of the PPARγ LBP. In PPARγ reporter gene assays, the degree of transactivation by both MCFAs and MUFAs peak at certain chain lengths [199, 203], possibly reflecting the ligand: receptor binding geometries and -stoichiometries available to a given fatty acid. Furthermore, the simultaneous binding of 15-oxoicosatetraenoic acid (15-oxoETE, Figure S2) and the serotonin metabolite 5-methoxyindole acetate (MIA, Figure S2) has been observed in the crystal phase. Notably, the maximum transcriptional activity induced by a combination of 15-oxoETE (10 μM) and MIA (100 μM) in a PPARγ reporter gene assay was roughly twice that induced by rosiglitazone (1 μM), while either 15-oxoETE or MIA alone, at the same concentrations, only induced about half the activity of rosiglitazone [66].

In parallel, while treatment of PPARγ with nonanoic acid or docosahexanoic acid (DHA) (Figure S1) inhibited Ser273
phosphorylation [199], treatment with a mixture of oleic and palmitic acid (Figure S1) [116], with palmitic acid alone [210] or with eicosapentaenoic acid (EPA, Figure S1) [211], appeared to promote this PTM. Interestingly, in the latter study, DHA induced a higher expression of adiponectin at 100 μM than at 200 μM [211].

Considering ligands of synthetic origin, the ligand BVT.13 [159, 212] (Figure S2) was observed to bind to PPARγ in a 1 : 1 stoichiometry in the crystal phase, primarily interacting with β3 and not with H12 [12, 114, 159]. And while HDX-MS experiments did not indicate that BVT.13 treatment stabilized H12 significantly compared to apo-PPARγ [114], the transcriptional response to BVT.13 was 60-80% of that of rosiglitazone, in PPARγ reporter gene assays [114, 159]. BVT.13 is also an inhibitor of Ser273 phosphorylation [116]. In contrast, 10 μM of the ligand GW0072 (Figure S2), which also appears to bind exclusively to the Ω pocket, displayed a maximum transcriptional activation of 20% of that induced by rosiglitazone (1 μM, 100%) in a PPARγ reporter gene assay. While data on the ability of GW0072 to inhibit phosphorylation of Ser273 is not available, GW0072 caused dissociation of NCoR from PPARγ [193]. However, it is noteworthy that GW0072 (10 μM) did not induce the expression of neither adipin nor fatty acid-binding protein 4 (FABP4/aP2) in 10T1/2 cells after up to 6 days, while rosiglitazone (1 μM) strongly upregulated both after 6 days [193].

Examples of negative cooperativity from the binding of multiple ligands of synthetic origin have also been reported. The ligand T2384 (Figure S2) displayed biphasic response curves in coregulator recruitment assays, with reduced recruitment of the coactivator MED1 (DRIP205) and increased recruitment of the corepressor NCoR at higher concentrations [197]. A similar biphasic coregulator recruitment pattern was also observed for the partial agonist telmisartan [176].

The phenomenon of multiple ligation of the PPARγ Ω pocket at higher ligand concentrations is paralleled by the binding of a single ligand in multiple conformations, as observed in the case of, e.g., SR1664 (Figure S1) [97, 101]. In the crystal phase, SR1664 was first shown to bind in a conformation similar to that of classical agonists, in which its interactions with Phe310(282) appeared to prevent it from functioning as an agonist [97, 98]. Bae et al. later demonstrated that SR1664 also binds to the Ω pocket (Figure 2(d)) and that this binding mode is likely of greater importance for its inhibition of Ser273 phosphorylation [101].

Taken together, these results paint a complex picture in which the binding of multiple molecules of the same or of different ligands is possible and may result in either positive or negative cooperativity in terms of transactivation. The collective efforts described above also illustrate that while inhibition of Ser273 phosphorylation likely requires interactions with regions of the PPARγ Ω pocket, a single consensus pharmacophore for the design of nonagonistic inhibitors of Ser273 phosphorylation has yet to be firmly established.

5.4. Clinical Applications of pSer273 Inhibitors. Interestingly, metabolic disease was not the only condition that could potentially be remediated by partial or nonagonistic PPARγ ligands. In a microarray analysis of the genes regulated by the murine, nonphosphorylatable Ser273Ala PPARγ mutant, Choi et al. revealed that two genes involved in myelination, neuroblast differentiation-associated protein AHNAK (Ahnak/desmoyokin) [213] and myelin proteolipid protein (Pplp1) [214], were also positively regulated [116]. PPARγ has been found in high concentrations in the cerebrospinal fluid of multiple sclerosis (MS) patients [215] and has been suggested to play a role in neuroprotection and remyelination [216, 217]. Although the cluster containing Ahnak and Plp1 was not as strongly upregulated by PPARγ ligands as by the Ser273Ala mutant [116], these findings suggested that inhibitors of PPARγ Ser273 phosphorylation may also be useful in the treatment of inflammation-related neurodegenerative diseases.

This dual therapeutic potential is exemplified in the account of the PPARγ partial agonist CHS-131 (formerly INT131, T0903131, T131, and AMG131, Figure S2) [156, 218, 219]. While CHS-131 (1–10 mg/day) displayed promising results in clinical trials oriented towards the treatment of metabolic diseases (NCT00952445 [220] and NCT00631007 [221]), it was later repurposed for the treatment of relapsing-remitting MS (RRMS) [222]. In 2016, upon completion of a 6-month phase IIb trial in patients with treatment-naïve RRMS, Coherus BioSciences Inc. reported that CHS131 decreased cumulative contrast-enhancing (CE) and T2 lesions, as well as cortical volume loss in the treatment group (NCT02638038) [223, 224]. In the former, metabolism-oriented trials, dose-dependent, yet less severe side effects were observed [220], comparing CHS131 to the PPARγ classical agonist pioglitazone (Figure S2) on parameters such as hemodilution and edema. No bone demineralization was observed with CHS-131, although the study was not powered to statistically evaluate this effect against that of pioglitazone [221]. In the RRMS trial, no serious side effects were noted at the employed effective dose (3 mg/day) [223, 224]. On the background of the gene expression data for rosiglitazone versus that of the weak partial agonist MRL24, reported by Choi et al. [116], these clinical observations can also be interpreted to provide support for the notion that the observed side effects of PPARγ classical agonists stem from the broader gene set they induce.

In the context of this review, the apparent clinical efficacy and safety of CHS-131 are of particular interest since, as a PPARγ ligand, CHS-131 may be characterized as a partial classical agonist based on its observed activation of transcription in various PPARγ reporter gene assays (15-40% of the effect of rosiglitazone) [218, 219, 156]. This could suggest that more completely nonagonistic ligands may display even better safety profiles. Indeed, two studies report that structural modifications to CHS-131 can produce ligands with substantially lower transactivation capacities, without sacrificing affinity for PPARγ [218, 225].

Finally, as suggested by a recent study, a future clinical application of nontoxic inhibitors of PPARγ Ser273 phosphorylation may also include their use as adjuvants to chemotherapy, in cases in which increased levels of...
pSer273-PPARγy, resulting from DNA damage by cytotoxic agents, leads to reduced sensitivity to the chemotherapy [226].

6. Relationships between PTMs and Ligand Binding in PPARα

The available data on relationships between PTMs in the PPARα C-terminal domains (D–F) and ligand binding are limited, but include two reports describing the protein kinase C- (PKC-) mediated phosphorylation of PPARα and its effects on the propensity for ligand binding to confer either transactivation (PPRE-mediated transcription of target genes) or transrepression [227, 228]. Prompted by an earlier result linking the expression of PPARα to that of PKC in rat liver [229], Blanquart et al. demonstrated that the phosphorylation of PPARα at Ser179 and/or Ser230 by PKC increased both basal and ligand-induced transcription of target genes such as carnitine palmitoyltransferase 1 (CPT1) and PPARα in a human liver cancer cell line [227]. Conversely, pharmacological inhibition of PKC or the use of a nonphosphorylatable, Ser179Ala/Ser230Ala double mutant, reduced the ability of PPARα classical agonists like WY14643 (pirinixic acid) and GW7647 (Figure S3) to induce the expression of these target genes and increased both the basal and the ligand-induced PPARα-mediated transrepression of the basal expression of fibrinogen beta chain (FGB) [230, 231] in HepG2 cells [227]. Similarly, Paumelle et al. could demonstrate that PKC inhibition or use of the PPARα double mutant attenuated the lipopolysaccharide (LPS-) induced expression of the proinflammatory nuclear factor NF-kappa-B (NFkB) target gene inducible nitric oxide synthase (iNOS) in murine macrophages. The transrepression of LPS-induced iNOS expression was also observed upon treatment of PPARα with the agonist GW9578 (Figure S3) and the 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin (Figure S3). The authors further demonstrated that while the transrepression of iNOS expression was dependent on PPARα for both these ligands, pretreatment of murine macrophages or neutrophils with simvastatin also interfered with the ability of LPS-induced, immunoprecipitated PKCα to phosphorylate a generic target like histone H1 in an in vitro assay [228]. Nonetheless, taken together with the stronger transrepressive effect observed upon upstream inhibition of PPARα phosphorylation using PKC inhibitors, the transrepressive effects of PPARα treatment with WY14643, GW7647, or GW9578 alone, compared to DMSO controls, may indicate that ligand binding itself, at least in part, reduces the propensity for PPARα to be phosphorylated by PKC.

Structurally, PPARα Ser179 is located in the hinge region, close to the PPARα DBDs, while Ser230 is located in the H2-β1 loop, in similarity to the Cdk5 phosphorylation target Ser273 in PPARγ (Figure 3). Thus, the results described above could indicate that the H2-β1 loop is a region of general interest for ligand-sensitive PTMs in the PPAR LBDs.

Interestingly, in a later, independent study by Roy et al., it was confirmed that simvastatin is also a PPARα ligand (EC₅₀ = 4.26 μM) [232]. In this study, the authors also performed molecular docking of the simvastatin δ-lactone to the PPARα LBP and found that it bound to the Ω pocket, where it interacted with Leu331 and Tyr334 of β3. Subsequently, site-directed mutagenesis of these residues (Leu331-Met, Tyr334Asp) and evaluation in a PPARα reporter gene assay revealed that simvastatin was unable to activate transcription through the Leu331Met/Tyr334Asp mutant. Notably, similar results were obtained for mevastatin and its 6-hydroxylated, ring-opened analogue pravastatin (Figure S3) [232]. However, the propensity of statin δ-lactones to be converted to their 3,5-dihydroxy acids (Figure S3) through hydrolysis or metabolism [233–236] raises the question of whether the observed effects of PPARα treatment with statins stem from the binding of the intact δ-lactones, the 3,5-dihydroxy acids, or both.

Nevertheless, Roy et al. demonstrated that treatment of murine astrocytes with simvastatin led to an upregulation of neurotrophin 3 (NT-3) and brain-derived neurotrophic factor (BDNF) which was dependent on cAMP response element-binding protein (CREB), whose expression is in turn regulated by PPARα [232]. The transcriptional regulation of CREB by PPARα appears to play a central role in hippocampal neuron plasticity and spatial memory consolidation in mice [237]. These results suggest a potential for PPARα-targeting ligands that regulate CREB expression in the treatment of neurodegenerative diseases such as Alzheimer’s disease [238, 239].

In summary, additional studies are needed to elucidate whether both of the discussed PKC phosphorylation sites in PPARα are involved in the observed effects, to what degree their phosphorylation is sensitive to ligand binding and what the binding modes of such ligands are. Taken together, however, these results illustrate that a refinement of our understanding of the interplay between ligand binding modes, PTMs, and their combined physiological effects may be instrumental towards harnessing the therapeutic potentials of PPARα ligands that do not necessarily share the transcriptional profiles of classical agonists.

6.1. PPARα Ligands with Alternative Binding Modes. So far, few ligands have been reported to display alternative binding modes in the PPARα LBP. In the crystal phase, Bernardes et al. observed that while one molecule of WY14643 bound in a conformation akin to other PPARα classical agonists, a second molecule bound to a novel site under the Ω loop (Figure 4). This binding mode strongly stabilized the Ω loop, as observed both in the crystal phase and with MD simulations [119]. Of particular interest in the context of the studies on the possible PKC-mediated phosphorylation of PPARα Ser230 described above, MD simulations also demonstrated that the binding of the second molecule of WY14643 stabilized the Ser230-containing H2-β1 loop (Figure 3) [119].

Finally, during the development of the Ω pocket-binding PPARα ligand BVT.13 [159, 212], described in Section 5.3, three additional ligands, BVT.762, BVT.763, and Compound 5d (Figure S3), also displayed binding to PPARα (Ki = 25 μM, 20 μM, and 19 μM, respectively) and induced transcription in a PPARα reporter gene assay...
Although no data is available on their binding modes in experimentally determined PTM-like modifications of the PPARα LBD are contained within a curated entry in the PhosphoSitePlus database. This entry denotes the immunohistochemical- and mass spectrometrical detection of PPARβ/δ apparently phosphorylated at Thr252, Thr253, and Thr256 on H3 by ribosomal protein S6 kinase alpha-3 (RPS6KA3), also known as p90 ribosomal S6 kinase 2 (RSK2) [240]. Consequently, no further details exist on the function or ligand sensitivity of these PTMs. Structurally, the partially buried localization of Thr252, Thr253, and Thr256 raises the question of whether they are indeed plausible PTM sites. It is noteworthy, however, that RSK2 has been reported to interact with an overlapping region in the human estrogen receptor α (hERα, residues 326-394, including H1, the H1-H3 loop, H3, H4, and H5) [241].

7.1. PPARβ/δ Ligands with Alternative Binding Modes. In studies of PPARβ/δ, ligands that display binding modes other than those of classical agonists have also been described. Shearer et al. reported a series of potently binding partial agonists, some of which were intriguingly poor inducers of transcription. Compound 34, Compound 13, and Compound 14 (Figure S4) displaced a radioligand with an EC50 = 13 nM, 3 nM, and 10 nM, respectively. In a cell-based reporter gene assay, Compound 34 and Compound 13 displayed an EC50 = 0.2 μM and an EC50 = 1.3 μM, with 29% and 37% maximal activation, respectively. The transcriptional activation observed with Compound 14, on the other hand, was below the sensitivity threshold of the reporter gene assay (~20%). In comparison, the classical agonist GW501516 (Figure S4) displayed an IC50 = 5 nM and an EC50 = 3 nM (98% maximal activation) in the same assays. In a crystal structure of PPARβ/δ in complex with the original high-throughput screening (HTS) hit, GW9371 (Figure S4, EC50 = 1.3 μM, 61% maximal activation), the ligand bound around H3, with its tetrahydroisoquinoline moiety protruding into the AF-2 pocket [242]. In contrast to the polar interactions common to the carboxylic acid head groups of classical agonists such as GW0742 (Figure S1), the distal aryl ring in GW9371 appears to display primarily hydrophobic interactions with the surrounding residues, among them Tyr437 of H12 (Figures 5(a) and 5(b)). Compound 13 and Compound 14 are structural analogues of GW9371 in which the hydrogen in the 5-position of its tetrahydroisoquinoline ring (Figure 5(b), teal sphere) has been substituted with a formic acid or a 2-oxyacetic acid, respectively (see Figure S4). While, as the authors suggest, the introduction of these substituents may have affected the membrane permeability of the resulting ligands [242], it is also possible that the diminished agonistic activities of Compound 13 and Compound 14 compared to GW9371 owe to the bulkiness of their AF-2 pocket-binding moieties, which may cause them to display H12-mediated antagonism (see Section 3).

Keil et al. described a series of ligands that interacted with H12 to a lesser degree than the GW series described above, binding in a U-shaped conformation around Cys249 (e.g., Compound 6, Figure 5(c) and Figure S4). From the extensive structure-activity relationships in all three PPARs established by the authors, a relevant ligand in this context was Compound 11j (Figure S4), which displayed...
Ω surfaces were mapped with a 1.4 Å probe using HOLLOW [102], and the resulting population of probes was truncated at the solvent visibility of the LBP. (a) Classical agonist, GW0742 (PDB ID: 3TKM) [245]. (b) Partial agonist GW9371 (PDB ID: 3DY6) [242]. The side –β from the ligand are shown with grey carbons. Plausible hydrogen bonds are shown with green dashes. H12 is shown in orange, and –β ligand in the pocket. The structures and surfaces were visualized in PyMOL (ver. 1.8.4.0) [13, 14].

In a genome-wide analyses of the transcriptional regulation by PPARβ/δ in myofibroblasts treated with a classical agonist such as GW501516 or L-165,041 (Figure S4), or with PPARD siRNA, Adhikary et al. demonstrated distinct modes of transcriptional response among PPARβ/δ target genes, including their individual ligand inducibilities [244]. If applied to nonclassical ligands such as Compound 14 (above) or Compound 11j, analyses in the same vein could reveal distinct regulatory patterns of therapeutic relevance. In summary, Compound 14 and Compound 11j represent valuable pharmacological tools to compare the transcriptional effects of weak partial agonists to those of classical agonists that actively stabilize PPARβ/δ H12.

8. Pharmacological Tools and Recent Advances in the Development of Ligands for the PPAR Ω Pockets

8.1. PPARγ. It has been observed that while treatment of PPARγ with ligands that bind covalently to the central cysteine residue, Cys313(285), such as GW9662 [71] or T0070907 [83] (Figure S2), limits the access to the AF-2 pocket (i.e., antagonizes the action of classical agonists), it does not inhibit the subsequent binding of an additional ligand in the Ω pocket [68, 101]. This phenomenon aligns with the numerous previous observations of the capacity of the PPARγ LBP to house multiple ligands simultaneously, as discussed in Section 5.3. Consequently, pharmacological and physiological (re)interpretations of the effects of treatment of PPARγ with this class of antagonists should reflect the possibility of interference from ligands that bind to the Ω pocket of the covalently modified receptor [68]. The notion that such interference could be pharmacologically relevant is substantiated by the observation that, in similarity to the synergistic activation observed upon simultaneous binding of multiple MCFAs [199, 203], the binding of a second ligand to PPARγ treated with GW9662 produced a stronger response in a PPARγ reporter gene assay than that observed with the ligand alone [246]. The classical PPARγ agonist MRL20 (Figure S2) has also been demonstrated to retain its ability to activate PPARγ after treatment with GW9662 or T0070907 by binding to the Ω pocket in a pose that was markedly different [68] from its crystallographically observed pose in untreated PPARγ (PDB ID: 2Q59) [114]. Thus, to address the “single-sided” antagonism of GW9662 and T0070907, Brust et al. recently designed analogues of these ligands, with bulkier groups protruding into the Ω pocket, blocking the binding of MRL20 [67].

On the other hand, the persistent ligand binding ability of the Ω pocket in PPARγ treated with GW9662 or T0070907 also opened up the possibility to use the covalently modified protein as a model in which to screen for new Ω pocket binders. Indeed, Ohtera et al. developed a method to screen a natural product extract library for the ability of the tested fractions to cooperatively activate transcription in a PPARγ reporter gene assay, upon cotreatment with GW9662 [246]. This allowed the authors to identify a methoxyphenylcinnamic ester ligand and further combine its structure with that of GW9662 to produce a hybrid partial agonist, Compound 5 (Figure S2), that bound covalently to Cys313(285) and likely occupied the Ω pocket (supported by molecular modelling) [246]. The ability of Compound 5 to inhibit PPARγ Ser273 phosphorylation was not investigated. In a later study, Bae et al. prepared a series of analogues of GW9662 which were shown by X-ray crystallography to bind covalently to Cys313(285), as well as to occupy the Ω pocket [101]. These ligands were designed to place an aryl moiety in a specific region between H3, β3, and β4 (see Section 5.3). The most promising of the resulting ligands, SB1405 and SB1453 (Figure S2), were shown to be potent inhibitors of Ser273 phosphorylation and practically devoid of classical agonism [101]. These results suggest that the covalent PPARγ partial agonist, L-764406 (Figure S2),
reported by Elbrecht et al. in 1999 [84], may also be capable of inhibiting Ser273 phosphorylation. During their studies, Bae et al. also prepared the N-methyl analogue of GW9662, SB1404 (Figure S2) [101], which given its marginal occupation of the Ω pocket may prove interesting in the context of screening campaigns similar to that of Ohtera et al. described above [246]. In the design of kinase inhibitors [247, 248], Serafimova et al. and Miller et al. took advantage of the reversibility of the 1,4-addition of thiolates to highly activated electrophiles, such as acrylonitriles [249]. Using this strategy, Kim et al. recently prepared and tuned a series of reversibly covalent and selective inhibitors of PPARγ Ser273 phosphorylation [250]. In a recent report by Jang et al., the crystal structure of PPARγ in complex with the most promising of the resulting ligands, SB1495 (Figure S2), demonstrated that SB1495 bound primarily to Ω pocket, where it stabilized the β-sheet region, H2′, and the Ω loop [251]. Given its covalent, reversible mode of action, ligands such as SB1495 may thus pave the way for more clinically efficacious, yet nontoxic inhibitors of PPARγ Ser273 phosphorylation.

8.2. PPARα and PPARβ/δ. GW9662, which targets Cys313(285) in PPARγ, has been reported to also covalently modify PPARα and PPARβ/δ [71]. In PPARα, Cys275 appears to be more reactive than its homologue Cys276 [76], which corresponds to Cys313(285) in PPARγ. The side chain of Cys275 also points more directly into the Ω pocket than that of Cys276. Regardless of their position, both these cysteine residues may be favourably utilized in the design of electrophilic ligands for the PPARα Ω pocket.

In the field of PPARβ/δ, on the other hand, several members of the 5-trifluoromethyl-2-sulfonylpyridine class of covalent antagonists, such as GSK3787 [72], CC618 [73], and Compound 37 [74] (Figure S4) have been reported. While these ligands differed in their selectivity for PPARβ/δ versus the other PPAR subtypes and in their rate of reaction with Cys249 [74], treatment of PPARβ/δ with either of these ligands resulted in the formation of a Cys249 5-trifluoromethyl-2-pyridyl thioether [75]. Although the aryl moiety appended to PPARβ/δ Cys249 is less bulky than the moiety appended to PPARγ Cys313 by treatment with GW9662, T0070907, or SB1404, this modification still inhibited activation of PPARβ/δ by classical agonists whose head groups bind to the AF-2 pocket, such as GW501516 or GW0742 (Figure S4) [72–74, 252]. Treatment of PPARβ/δ with CC618 or GSK3787 alone did not induce transcription in reporter gene assays [72, 252] nor did treatment with GSK3787 cause the recruitment of the coactivator MED1 (TRAP220) in a TR-FRET-based assay [252]. In a similar assay, treatment with GSK3787 did however result in a moderate, but statistically significant dissociation from the corepressors NCoR and SMRT compared to apo-PPARβ/δ [252]. Whether PPARβ/δ covalently modified at Cys249 is still capable of binding additional ligands in its Ω pocket has yet to be investigated. More importantly, the transcriptional effects of this type of multiple ligation are also unknown. Thus, for the identification of ligands that bind to the PPARβ/δ Ω pocket, other screening methodologies than that of Ohtera et al. [246] described in the previous section may require consideration.

To that end, recent studies of PPARγ have highlighted that 19F NMR represents a powerful technique to study the binding of fluorine-containing ligands to both the AF-2 pocket and the Ω pocket [68, 107]. Chrisman et al. also demonstrated that the effects of the binding of several classes of nonfluorinated ligands on the conformational dynamics of PPARγ could be characterized with 19F NMR, after covalent modification of mutagenetically introduced cysteine residues in H3 and H12 with a trifluoroacetone probe [87]. Thus, in the context of screening for ligands that bind to the Ω pocket of PPARβ/δ treated with the 5-trifluoromethyl-2-sulfonylpyridine class of covalently modifying ligands, the relative proximity of the Cys249 5-trifluoromethyl-2-pyridylthioether to a ligand binding in the Ω pocket suggests that a 19F NMR-based assay may be viable.

9. Conclusions

Herein, we have described discoveries and collective efforts from recent years that have promoted a more nuanced understanding of the pharmacology of PPARγ—an understanding that has already had important ramifications for both PPARγ-targeting therapy and further drug development. These achievements have occurred within a framework that integrates the study of ligand binding, PTMs, protein-protein interactions, and their combined effects on transcription. Collectively, the results obtained within this framework have signalled a shift in interest, away from classical PPARγ agonists that induce supraphysiological levels of unselective transcriptional activation, to the development of nonagonistic- and other noncanonical ligands that more selectively influence gene expression patterns by modulating the occurrence of PTMs. A common theme among many of these new ligands is their binding to the PPARγ Ω pocket. We have ventured to show that the application of these emerging principles to the study of PPARα and PPARβ/δ can potentially provide new insights, e.g., through the identification of ligand-sensitive PTMs and the study of their effects on gene expression patterns, but also through the application of known ligands with alternative binding modes in new assay contexts. The data generated by such efforts would lay the foundation for the development of new generations of drugs targeting PPARα and PPARβ/δ.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

We would like to thank current and past coworkers for fruitful collaborations and experimental and methodological efforts. The Norwegian Research Council is gratefully acknowledged for generously funding T.V.H through KOSK
The chemical structures of the ligands described in the contexts of PPARγ, PPARα, and PPARβ/δ are depicted in their order of appearance in Figures S1–S4 in the Supplementary Material. (Supplementary Materials)

References

[1] The UniProt Consortium, “UniProt: a hub for protein information,” Nucleic Acids Research, vol. 43, no. D1, pp. D204–D212, 2015.
[2] H. E. Xu and Y. Li, “Ligand-dependent and -independent regulation of PPARγ and orphan nuclear receptors,” Science Signaling, vol. 1, no. 48, article pe52, 2008.
[3] S. Hummasti and P. Tontonoz, “The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis,” Molecular Endocrinology, vol. 20, no. 6, pp. 1261–1275, 2006.
[4] R. M. Evans and D. J. Mangelsdorf, “Nuclear receptors, RXR, and the big bang,” Cell, vol. 157, no. 1, pp. 255–266, 2014.
[5] C. Juge-Aubry, A. Pernin, T. Favez et al., “DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements: importance of the 5′-flanking region,” Journal of Biological Chemistry, vol. 272, no. 40, pp. 25252–25259, 1997.
[6] D. G. Lemay and D. H. Wang, “Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics,” The Journal of Lipid Research, vol. 47, no. 7, pp. 1583–1587, 2006.
[7] F. Rastinejad, V. Ollendorff, and I. Polikarpov, “Nuclear receptor full-length architectures: confronting myth and illusion with high resolution,” Trends in Biochemical Sciences, vol. 40, no. 1, pp. 16–24, 2015.
[8] S. A. Kliever, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors,” Nature, vol. 358, no. 6389, pp. 771–774, 1992.
[9] T. Venäläinen, F. Molnár, C. Oostenbrink, C. Carlberg, and M. Peräkylä, “Molecular mechanism of allosteric communication in the human PPARα-RXRα heterodimer,” Proteins, vol. 78, no. 4, pp. 873–887, 2010.
[10] H. Zhang, X. Xu, L. Chen et al., “Molecular determinants of magnolol targeting both RXRα and PPARγ,” PLoS One, vol. 6, no. 11, article e28253, 2011.
[11] D. J. Kojetin, E. Matta-Camacho, T. S. Hughes et al., “Structural mechanism for signal transduction in RXR nuclear receptor heterodimers,” Nature Communications, vol. 6, no. 1, article 8013, 2015.
[12] V. Chandra, P. Huang, Y. Hamuro et al., “Structure of the intact PPARγ-RXR-α nuclear receptor complex on DNA,” Nature, vol. 456, no. 7220, pp. 350–356, 2008.
[13] L. L. C. Schrödinger, The PyMOL Molecular Graphics System, Version 1.8, 2015.
[14] W. L. Delano, “PyMOL: An Open-Source Molecular Graphics Tool,” CCP4 Newsletter On Protein Crystallography, vol. 40, pp. 82–92, 2002.
necessary and sufficient to prevent liver fibrosis in mice," *Hepatology*, vol. 60, no. 5, pp. 1593–1606, 2014.

[32] N. Perez-Diaz and L. Mackenzie, “Linking induction and transrepression of PPARα/δ with cellular function,” *Annual Research & Review in Biology*, vol. 6, no. 4, pp. 253–263, 2015.

[33] M. Ricote and C. Glass, “PPARs and molecular mechanisms of transrepression,” *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*, vol. 1771, no. 8, pp. 926–935, 2007.

[34] C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPAR,” *Science*, vol. 302, no. 5644, pp. 453–457, 2003.

[35] G. Pascual and C. K. Glass, “Nuclear receptors versus inflammation: mechanisms of transrepression,” *Trends in Endocrinology & Metabolism*, vol. 17, no. 8, pp. 321–327, 2006.

[36] S. J. Bensinger and P. Tontonoz, “Integration of metabolism and inflammation by lipid-activated nuclear receptors,” *Nature*, vol. 454, no. 7203, pp. 470–477, 2006.

[37] S. Kersten, “Integrated physiology and systems biology of PPARα,” *Molecular Metabolism*, vol. 3, no. 4, pp. 354–371, 2014.

[38] E. D. Rosen and B. M. Spiegelman, “Adipocytes as regulators of energy balance and glucose homeostasis,” *Nature*, vol. 444, no. 7121, pp. 847–853, 2006.

[39] M. F. Oliver, I. A. Heady, J. N. Morris, and J. Cooper, “WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up: report of the committee of principal investigators: report of the Committee of Principal Investigators,” *The Lancet*, vol. 324, no. 8403, pp. 600–604, 1984.

[40] B. Qu, Q.-T. Li, K. P. Wong, T. M. C. Tan, and B. Halliwell, “Mechanism of clofibrate hepatotoxicity: mitochondrial damage and oxidative stress in hepatocytes,” *Free Radical Biology and Medicine*, vol. 31, no. 5, pp. 659–669, 2001.

[41] S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” *The New England Journal of Medicine*, vol. 356, no. 24, pp. 2457–2471, 2007.

[42] D. M. Nathan, “Rosiglitazone and cardiotoxicity — weighing the evidence,” *The New England Journal of Medicine*, vol. 357, no. 1, pp. 64–66, 2007.

[43] M. Komajda, J. V. McMurray, H. Beck-Nielsen et al., “Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial,” *European Heart Journal*, vol. 31, no. 7, pp. 824–831, 2010.

[44] M. Ferwana, B. Firwana, R. Hasan et al., “Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies,” *Diabetic Medicine*, vol. 30, no. 9, pp. 1026–1032, 2013.

[45] J. D. Lewis, L. A. Habel, C. P. Quesenberry et al., “Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes,” *JAMA*, vol. 314, no. 3, pp. 265–277, 2015.

[46] S. E. Nissen, K. Wolski, and E. J. Topol, “Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus,” *JAMA*, vol. 294, no. 20, pp. 2581–2586, 2005.

[47] G. G. Long, V. L. Reynolds, L. W. Dochterman, and T. E. Ryan, “Neoplastic and non-neoplastic changes in F-344 rats treated with navelglitazar, a γ-dominant PPAR α/γ agonist,” *Toxicologic Pathology*, vol. 37, no. 6, pp. 741–753, 2009.

[48] M. B. Oleksiewicz, J. Southgate, L. Iversen, and F. L. Egerod, “Rat urinary bladder carcinogenesis by dual-acting PPARα-γ agonists,” *PPAR Research*, vol. 2008, Article ID 103167, 14 pages, 2008.

[49] H. Hellmold, H. Zhang, U. Andersson et al., “Tesaglitazar, a PPARα/γ agonist, induces intestinal mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats,” *Toxicological Sciences*, vol. 98, no. 1, pp. 63–74, 2007.

[50] F. L. Egerod, H. S. Nielsen, L. Iversen, I. Thorup, T. Storgaard, and M. B. Oleksiewicz, “Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urotheium in vivo,” *Biomarkers*, vol. 10, no. 4, pp. 295–309, 2008.

[51] C. Helsen and F. Claessens, “Looking at nuclear receptors from a new angle,” *Molecular and Cellular Endocrinology*, vol. 382, no. 1, pp. 97–106, 2014.

[52] A. Bernarides, F. A. H. Batista, M. de Oliveira Neto et al., “Low-resolution molecular models reveal the oligomeric state of the PPAR and the conformational organization of its domains in solution,” *PLoS One*, vol. 7, no. 2, article e31852, 2012.

[53] A. Bugge and S. Mandrup, “Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation,” *PPAR Research*, vol. 2010, Article ID 169506, 12 pages, 2010.

[54] A. Werman, A. Hollenberg, G. Solanes, C. Bjørbæk, A. J. Vidal-Puig, and J. S. Flier, “Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ),” *Journal of Biological Chemistry*, vol. 272, no. 32, pp. 20230–20235, 1997.

[55] L. Gelman, G. Zhou, L. Fajas, E. Raspé, J.-C. Fruchart, and J. Auwerx, “P300 interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner, respectively,” *Journal of Biological Chemistry*, vol. 274, no. 12, pp. 7681–7688, 1999.

[56] R. Hi, S. Osada, N. Yumoto, and T. Osumi, “Characterization of the amino-terminal activation domain of peroxisome proliferator-activated receptor α,” *Journal of Biological Chemistry*, vol. 274, no. 49, pp. 35152–35158, 1999.

[57] M. Aprile, M. R. Ambrosio, V. D’Esposito et al., “PPARG in human adipogenesis: differential contribution of canonical transcripts and dominant negative isoforms,” *PPAR Research*, vol. 2014, Article ID 537865, 11 pages, 2014.

[58] J. C. Hanselman, M. V. Vartanian, B. P. Koester et al., “Expression of the mRNA encoding truncated PPAR alpha does not correlate with hepatic insensitivity to peroxisome proliferators,” *Molecular and Cellular Biochemistry*, vol. 217, no. 1/2, pp. 91–97, 2001.

[59] K. Lundell, P. Thulin, A. Hamsten, and E. Ehrenborg, “Alternative splicing of human peroxisome proliferator-activated receptor delta (PPARDelta)effects on translation efficiency and trans-activation ability,” *BMC Molecular Biology*, vol. 8, no. 1, p. 70, 2007.

[60] Y. Chen, A. R. Jimenez, and J. D. Medhi, “Identification and regulation of novel PPARγ splice variants in human THP-1 macrophages,” *Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression*, vol. 1759, no. 1-2, pp. 32–43, 2006.
Å. Kaupang, E. T. Kase, C. X. T. Vo, M. Amundsen, A. Vik, and T. V. Hansen, "Synthesis of 5-trifluoromethyl-2-sulfonylpyridine PPARβ/δ antagonists: effects on the affinity and selectivity towards PPARβ/δ," Bioorganic & Medicinal Chemistry, vol. 24, no. 2, pp. 247–260, 2016.

Å. Kaupang, S. Hildon, T. G. Halvorsen, M. Mortén, A. Vik, and T. V. Hansen, "Involvement of covalent interactions in the mode of action of PPARβ/δ antagonists," RSC Advances, vol. 5, no. 93, pp. 76483–76490, 2015.

B. Shearer, R. W. Wiethe, A. Ashe et al., "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ," Nature, vol. 395, no. 6698, pp. 137–143, 1998.

R. T. Nolte, G. B. Wisely, S. Westin et al., "Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ," Journal of Biological Chemistry, vol. 273, no. 47, pp. 31108–31112, 1998.

Å. Kaupang, S. Hildonen, T. G. Halvorsen, M. Mortén, L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe et al., "The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites," The EMBO Journal, vol. 29, no. 19, pp. 3395–3407, 2010.

R. Brust, H. Lin, J. Fuhrmann, A. Asteian, T. M. Kamenecka, and D. J. Kojetin, "Modification of the orthosteric PPARγ core antagonist scaffold yields an improved dual-site allosteric inhibitor," ACS Chemical Biology, vol. 12, no. 4, pp. 969–978, 2017.

T. S. Hughes, P. K. Giri, I. M. S. de Vera et al., "An alternate binding site for PPARγ ligands," Nature Communications, vol. 5, no. 1, article 3571, 2014.

V. Zoete, A. Grosdidier, and O. Michielin, "Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators," Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 915–925, 2007.

H. M. Berman, J. Westbrook, Z. Feng et al., "The protein data bank," Nucleic Acids Research, vol. 28, no. 1, pp. 235–242, 2000.

L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe et al., "Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662," Biochemistry, vol. 41, no. 21, pp. 6640–6650, 2002.

B. G. Sherrar, R. W. Wiethe, A. Ashe et al., "Identification and characterization of 4-chloro-N-2,5-trifluoromethyl-2-pyridylsulfonylbenzenzamide GSK3787, a selective and irreversible peroxisome proliferator-activated receptor δ PPARδ antagonist," Journal of Medicinal Chemistry, vol. 53, no. 4, pp. 1857–1861, 2010.

Å. Kaupang, S. M. Paulsen, C. C. Steindal et al., "Synthesis, biological evaluation and molecular modeling studies of the PPARβ/δ antagonist CC618," European Journal of Medicinal Chemistry, vol. 94, pp. 229–236, 2015.

Å. Kaupang, E. T. Kase, C. T. T. Vo, M. Amundsen, A. Vik, and T. V. Hansen, "Synthesis of 5-trifluoromethyl-2-sulfonylpyridine PPARβ/δ antagonists: effects on the affinity and selectivity towards PPARβ/δ," Bioorganic & Medicinal Chemistry, vol. 24, no. 2, pp. 247–260, 2016.

Å. Kaupang, S. Hildonen, T. G. Halvorsen, M. Mortén, A. Vik, and T. V. Hansen, "Involvement of covalent interactions in the mode of action of PPARβ/δ antagonists," RSC Advances, vol. 5, no. 93, pp. 76483–76490, 2015.

D. Egawa, T. Itoh, Y. Akiyama, T. Saito, and K. Yamamoto, "17-OxoDHA is a PPARαγ dual covalent modifier and agonist," ACS Chemical Biology, vol. 11, no. 9, pp. 2447–2455, 2016.

D. Egawa, T. Itoh, and K. Yamamoto, "Characterization of covalent bond formation between PPARγ and oxo-fatty acids," Bioconjugate Chemistry, vol. 26, no. 4, pp. 690–698, 2015.

T. Waku, T. Shiraki, T. Oyama et al., "Structural insight into PPARγ activation through covalent modification with endogenous fatty acids," Journal of Molecular Biology, vol. 385, no. 1, pp. 188–199, 2009.

T. Waku, T. Shiraki, T. Oyama, and K. Morikawa, "Atomic structure of mutant PPARγ LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARγ/RXRα function by covalently bound ligands," FEBS Letters, vol. 583, no. 2, pp. 320–324, 2009.

T. Itoh, L. Fairall, K. Amin et al., "Structural basis for the activation of PPARγ by oxidized fatty acids," Nature Structural & Molecular Biology, vol. 15, no. 9, pp. 924–931, 2008.

F. J. Schopfer, M. P. Cole, A. L. Groeger et al., "Covalent peroxisome proliferator-activated receptor γ addiction by nitrofatty acids," Journal of Biological Chemistry, vol. 285, no. 16, pp. 12321–12333, 2010.

Y. Li, J. Zhang, F. J. Schopfer et al., "Molecular recognition of nitrated fatty acids by PPARγ," Nature Structural & Molecular Biology, vol. 15, no. 8, pp. 865–867, 2008.

G. Lee, F. Elwood, J. McNally et al., "T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities," Journal of Biological Chemistry, vol. 277, no. 22, pp. 19649–19657, 2002.

A. Elbrecht, Y. Chen, A. Adams et al., "L-764406 is a partial agonist of human peroxisome proliferator-activated receptor γ," Journal of Biological Chemistry, vol. 274, no. 12, pp. 7913–7922, 1999.

H. E. Xu, T. B. Stanley, V. G. Montana et al., "Structural basis for antagonist-mediated recruitment of nuclear corepressors by PPARα," Nature, vol. 415, no. 6873, pp. 813–817, 2002.

M. R. B. Batista and L. Martinez, "Conformational diversity of the helix 12 of the ligand binding domain of PPARα and functional implications," The Journal of Physical Chemistry B, vol. 119, no. 50, pp. 15418–15429, 2015.

I. M. Chrisman, M. D. Nemetchek, I. M. S. de Vera et al., "Defining a conformational ensemble that directs activation of PPARγ," Nature Communications, vol. 9, no. 1, article 1794, 2018.

R. L. Frkic, A. C. Marshall, A.-L. Blayo et al., "PPARγ in complex with an antagonist and inverse agonist: a tumble and trap mechanism of the activation helix," iScience, vol. 5, pp. 69–79, 2018.

H. E. Xu, M. H. Lambert, V. G. Montana et al., "Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13919–13924, 2001.

Y. Hashimoto and H. Miyachi, "Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis," Bioorganic & Medicinal Chemistry, vol. 13, no. 17, pp. 5080–5093, 2005.
with pure antagonistic or inverse agonistic properties.

[107] T. S. Hughes, M. J. Chalmers, S. Novick et al., "Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism," Structure, vol. 20, no. 1, pp. 139–150, 2012.

[108] J. Lu, M. Chen, S. E. Stanley, and E. Li, "Effect of heterodimer partner RXRs on PPARγ activation function-2 helix in solution," Biochemical and Biophysical Research Communications, vol. 365, no. 1, pp. 42–46, 2008.

[109] R. Hartl, Berechnung Der NMR-Struktur Der PPARgamma-LBD Und Hochdruck-NMR-Messungen an HPr 114A, University of Regensburg, Germany, 2008.

[110] H. Riepl, R. Hartl, M. Bauer et al., "Sequential backbone assignment of peroxisome proliferator-activated receptor-γ ligand binding domain," Journal of Biomolecular NMR, vol. 32, no. 3, p. 259, 2005.

[111] B. A. Johnson, E. M. Wilson, Y. Li, D. E. Moller, R. G. Smith, and G. Zhou, "Ligand-induced stabilization of PPARγ monitored by NMR spectroscopy: implications for nuclear receptor activation," Journal of Molecular Biology, vol. 298, no. 2, pp. 187–194, 2000.

[112] S.-S. Choi, E.-S. Kim, J.-E. Jung et al., "PPARγ antagonist Gleevec improves insulin sensitivity and promotes the browning of white adipose tissue," Diabetes, vol. 65, no. 4, pp. 829–839, 2016.

[113] D. P. Marciano, D. S. Kuruvilla, B. D. Pascal, and P. R. Griffin, "Identification of bexarotene as a PPARγ antagonist with HDX," PPAR Research, vol. 2015, Article ID 254560, 6 pages, 2015.

[114] J. B. Bruning, M. J. Chalmers, S. Prasad et al., "Partial agonists activate PPARγ using a helix 12 independent mechanism," Structure, vol. 15, no. 10, pp. 1258–1271, 2007.

[115] A. A. Amato, S. Rajagopalan, J. Z. Lin et al., "GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain," Journal of Biological Chemistry, vol. 287, no. 33, pp. 28169–28179, 2012.

[116] J. H. Choi, A. S. Banks, J. L. Estall et al., "Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5," Nature, vol. 466, no. 7305, pp. 451–456, 2010.

[117] Y. Hamujo, S. J. Coales, J. A. Morrow et al., "Hydrogen/deuterium-exchange (H/D-ex) of PPARβ LBD in the presence of various modulators," Protein Science, vol. 15, no. 8, pp. 1883–1892, 2006.

[118] J. A. Lemkul, S. N. Lewis, J. Bassaganya-Riera, and D. R. Bevan, "Phosphorylation of PPARγ affects the collective motions of the PPARγ-RXR-DNA complex," PLoS One, vol. 10, no. 5, article e0123984, 2015.

[119] A. Bernardes, P. C. T. Souza, J. R. C. Muniz et al., "Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization," Journal of Molecular Biology, vol. 425, no. 16, pp. 2878–2893, 2013.

[120] L. E. Geiger, W. S. Dunsford, D. J. Lewis, C. Brennan, K. C. Liu, and S. J. Newsholme, "Rat carcinogenicity study with GW501516, a PPAR delta agonist," in The Toxicologist: Supplement to Toxicological Sciences, vol. 108, no. 1, 2009 Society of Toxicology, 2009, Abstract no. 895.

[121] S. J. Newsholme, W. S. Dunsford, T. Brodie, C. Brennan, M. Brown, and L. E. Geiger, "Mice carcinogenicity study with GW501516, a PPAR delta agonist," in The Toxicologist:
Supplement to Toxicological Sciences, vol. 108, no. 1, 2009.

[122] J. H. Choi, A. S. Banks, T. M. Kamenecka et al., "Antidiabetic actions of a non-agonist PPARγ ligand blocking CdKδ-mediated phosphorylation," *Nature*, vol. 477, no. 7365, pp. 477–481, 2011.

[123] S.-S. Choi, J. Park, and J. H. Choi, "Revisiting PPARγ as a target for the treatment of metabolic disorders," *BMB Reports*, vol. 47, no. 11, pp. 599–608, 2014.

[124] W. Yi, J. Shi, G. Zhao et al., "Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro," *Scientific Reports*, vol. 7, no. 1, article 41487, 2017.

[125] T. Shinozuka, T. Tsukada, K. Fujii et al., "Discovery of DS-6930, a potent selective PPARγ modulator. Part I: lead identification," *Bioorganic & Medicinal Chemistry*, vol. 26, no. 18, pp. 5079–5098, 2018.

[126] T. Shinozuka, T. Tsukada, K. Fujii et al., "Discovery of DS-6930, a potent selective PPARγ modulator. Part II: lead optimization," *Bioorganic & Medicinal Chemistry*, vol. 26, no. 18, pp. 5099–5117, 2018.

[127] L. Porskjaer Christensen and R. Bahij El-Houri, "Development of an in vitro screening platform for the identification of partial PPARγ agonists as a source for antidiabetic lead compounds," *Molecules*, vol. 23, no. 10, article 2431, 2018.

[128] J.-S. Lee, E. Smith, and A. Shilatifard, "The language of histone crosstalk," *Cell*, vol. 142, no. 5, pp. 682–685, 2010.

[129] A. Sadakierska-Chudy and M. Filip, "A comprehensive view of the epigenetic landscape. Part II: histone post-translational modification, nucleosome level, and chromatin regulation by ncRNAs," *Neurotoxicity Research*, vol. 27, no. 2, pp. 172–197, 2015.

[130] R. Brunmeir and F. Xu, "Functional regulation of PPARs through post-translational modifications," *International Journal of Molecular Sciences*, vol. 19, no. 6, article 1738, 2018.

[131] M. Anbalagan, B. Huderson, L. Murphy, and B. G. Rowan, "Post-translational modifications of nuclear receptors and human disease," *Nuclear Receptor Signaling*, vol. 10, no. 1, 2018.

[132] W. Berrabah, P. Aumercier, P. Lefebvre, and B. Staels, "Control of nuclear receptor crosstalk in metabolism by post-translational modifications," *FEBS Letters*, vol. 585, no. 11, pp. 1640–1650, 2011.

[133] T.-H. Kim, M.-Y. Kim, S.-H. Jo, J.-M. Park, and Y.-H. Ahn, "Modulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modifications," *Yonsei Medical Journal*, vol. 54, no. 3, pp. 545–559, 2013.

[134] S. A. M. Laarseven der, A. C. Leney, and A. J. R. Heck, "Cross-talk between phosphorylation and O-GlcNAcylation: friend or foe," *The FEBS Journal*, vol. 285, no. 17, pp. 3152–3167, 2018.

[135] H. Xu, J. Zhou, S. Lin, W. Deng, Y. Zhang, and Y. Xue, "PLMD: an updated data resource of protein lysine modifications," *Journal of Proteins and Genomics*, vol. 44, no. 5, pp. 243–250, 2017.

[136] Z. Liu, Y. Wang, T. Gao et al., "CPLM: a database of protein lysine modifications," *Nucleic Acids Research*, vol. 42, no. D1, pp. D531–D536, 2013.

[137] Z. Liu, J. Cao, X. Gao et al., "CPLA1 1.0: an integrated database of protein lysine acetylation," *Nucleic Acids Research*, vol. 39, Supplement 1, pp. D1029–D1034, 2011.

[138] E. S. Johnson, "Protein modification by SUMO," *Annual Review of Biochemistry*, vol. 73, no. 1, pp. 355–382, 2004.

[139] S. Ross, J. L. Best, L. I. Zon, and G. Gill, "SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization," *Molecular Cell*, vol. 10, no. 4, pp. 831–842, 2002.

[140] I. A. Hendriks, D. Lyon, C. Young, L. J. Jensen, A. C. O. Vertegaal, and M. L. Nielsen, "Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation," *Nature Structural & Molecular Biology*, vol. 24, no. 3, pp. 325–336, 2017.

[141] S. H. Yang, A. Galanis, J. Witty, and A. D. Sharrocks, "An extended consensus motif enhances the specificity of substrate modification by SUMO," *The EMBO Journal*, vol. 25, no. 21, pp. 5083–5093, 2006.

[142] V. Hietakangas, J. Anckar, H. A. Blomster et al., "PDSM, a motif for phosphorylation-dependent SUMO modification," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 1, pp. 45–50, 2006.

[143] H. L. Rust and P. R. Thompson, "Kinase consensus sequences: a breeding ground for crosstalk," *ACS Chemical Biology*, vol. 6, no. 9, pp. 881–892, 2011.

[144] P. Li, W. Fan, J. Xu et al., "Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity," *Cell*, vol. 147, no. 4, pp. 815–826, 2011.

[145] L. Qiang, L. Wang, N. Kon et al., "Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ," *Cell*, vol. 150, no. 3, pp. 620–632, 2012.

[146] C. G. Ricci, R. L. Silveira, I. Rivalta, V. S. Batista, and M. S. Skaf, "Allosteric pathways in the PPARγ-RXRα nuclear receptor complex," *Scientific Reports*, vol. 6, no. 1, article 19940, 2016.

[147] W. Deng, C. Wang, Y. Zhang et al., "GPS-PAIL: prediction of lysine acetyltransferase-specific modification sites from protein sequences," *Scientific Reports*, vol. 6, no. 1, article 39787, 2016.

[148] "Kinexus | PhosphoNET," July 2018, http://www.phosphonet.ca.

[149] R. Amanchy, B. Periaswamy, S. Mathivanan, R. Reddy, S. G. Tattikota, and A. Pandey, "A curated compendium of phosphorylation motifs," *Nature Biotechnology*, vol. 25, no. 3, pp. 285–286, 2007.

[150] N. Blom, T. Sicheritz-Pontén, R. Gupta, S. Gammeltoft, and S. Brunak, "Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence," *Proteomics*, vol. 4, no. 6, pp. 1633–1649, 2004.

[151] N. Blom, S. Gammeltoft, and S. Brunak, "Sequence and structure-based prediction of eukaryotic protein phosphorylation sites," *Journal of Molecular Biology*, vol. 294, no. 5, pp. 1351–1362, 1999.

[152] P. V. Hornbeck, B. Zhang, B. Murray, J. M. Kornhauser, V. Latham, and E. Skrzypek, "PhosphoSitePlus, 2014: mutations, PTMs and recalibrations," *Nucleic Acids Research*, vol. 43, no. D1, pp. D512–D520, 2015.

[153] A. M. Sharma and B. Staels, "Peroxisome proliferator-activated receptor γ and adipose tissue—understanding obesity-related changes in regulation of lipid and glucose metabolism by post-translational regulation of PPARs, NURRs and their epigenetic landscape."
metabolism,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 92, no. 2, pp. 386–395, 2007.

[154] J. Nedergaard and B. Cannon, “The browning of white adipose tissue: some burning issues,” *Cell Metabolism*, vol. 20, no. 3, pp. 396–407, 2014.

[155] F. M. Gregoire, F. Zhang, H. J. Clarke et al., “MBX-102/JN19659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema,” *Molecular Endocrinology*, vol. 23, no. 7, pp. 975–988, 2009.

[156] L. S. Higgins and C. S. Mantzoros, “The development of INT131 as a selective PPARγ modulator: approach to a safer insulin sensitizer,” *PPAR Research*, vol. 2008, Article ID 936906, 9 pages, 2008.

[157] T. Allen, F. Zhang, S. A. Moodie et al., “Halofenate is a selective peroxisome proliferator–activated receptor γ modulator with antidiabetic activity,” *Diabetes*, vol. 55, no. 9, pp. 2523–2533, 2006.

[158] J. J. Acton III, R. M. Black, A. B. Jones et al., “Benzoyl 2-methyl indoles as selective PPARγ modulators,” *Bioorganic & Medicinal Chemistry Letters*, vol. 15, no. 2, pp. 357–362, 2005.

[159] T. Östberg, S. Svensson, G. Selén et al., “A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects,” *Journal of Biological Chemistry*, vol. 279, no. 39, pp. 41124–41130, 2004.

[160] J. P. Berger, A. E. Petro, K. L. Macnaul et al., “Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator,” *Molecular Endocrinology*, vol. 17, no. 4, pp. 662–676, 2003.

[161] S. Rocchi, F. Picard, J. Vamecq et al., “A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity,” *Molecular Cell*, vol. 8, no. 4, pp. 737–747, 2001.

[162] J. H. Choi, S.-S. Choi, E. S. Kim et al., “Thrap3 docks on phosphoserine 273 of PPARγ and controls diabetic gene programming,” *Genes & Development*, vol. 28, no. 21, pp. 2361–2369, 2014.

[163] A. S. Banks, F. E. McAllister, J. P. G. Camporez et al., “An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ,” *Nature*, vol. 517, no. 7534, pp. 391–395, 2015.

[164] Z. E. Floyd and J. M. Stephens, “Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ,” *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, vol. 1822, no. 7, pp. 1090–1095, 2012.

[165] A. W. Norris and C. D. Sigmund, “A second chance for a PPARγ targeted therapy?,” *Circulation Research*, vol. 110, no. 1, pp. 8–11, 2012.

[166] M. Ahmadian, J. M. Suh, N. Hah et al., “PPARγ signaling and metabolism: the good, the bad and the future,” *Nature Medicine*, vol. 19, no. 5, pp. 557–566, 2013.

[167] C. Guo, Y. Li, C.-H. Gow et al., “The optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2,” *Journal of Biological Chemistry*, vol. 290, no. 6, pp. 3666–3679, 2015.

[168] L. Tian, C. Wang, F. K. Hagen et al., “Acetylation-defective mutants of PPARγ are associated with decreased lipid synthesis in breast cancer cells,” *Oncotarget*, vol. 5, no. 17, pp. 7303–7315, 2014.

[169] H. Wang, L. Qiang, and S. R. Farmer, “Identification of a domain within peroxisome proliferator-activated receptor γ regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes,” *Molecular and Cellular Biology*, vol. 28, no. 1, pp. 188–200, 2008.

[170] M. J. Kraakman, Q. Liu, J. Postigo-Fernandez et al., “PPARY deacetylation dissociates thiazolidinedione’s metabolic benefits from its adverse effects,” *Journal of Clinical Investigation*, vol. 128, no. 6, pp. 2600–2612, 2018.

[171] L. Han, R. Zhou, J. Niu, M. A. McNutt, P. Wang, and T. Tong, “SIRT1 is regulated by a PPARγ–SIRT1 negative feedback loop associated with senescence,” *Nucleic Acids Research*, vol. 38, no. 21, pp. 7458–7471, 2010.

[172] P. Scale, H. M. Conroe, J. Estall et al., “Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice,” *Journal of Clinical Investigation*, vol. 121, no. 1, pp. 96–105, 2011.

[173] H. Ohno, K. Shinoda, B. M. Spiegelman, and S. Kajimura, “PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein,” *Cell Metabolism*, vol. 15, no. 3, pp. 395–404, 2012.

[174] H. Wang, L. Liu, J. Z. Lin, T. R. Aprahamian, and S. R. Farmer, “Browning of white adipose tissue with rosiglitazone induces a distinct population of UCP1+ adipocytes,” *Cell Metabolism*, vol. 24, no. 6, pp. 835–847, 2016.

[175] R. Mayoral, O. Osborn, J. McNelis et al., “Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity,” *Molecular Metabolism*, vol. 4, no. 5, pp. 378–391, 2015.

[176] T. Tagami, H. Yamamoto, K. Moriyama et al., “A selective peroxisome proliferator-activated receptor-γ modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones,” *Endocrinology*, vol. 150, no. 2, pp. 862–870, 2009.

[177] Y. Amano, T. Yamaguchi, K. Ohno et al., “Structural basis for telmisartan-mediated partial activation of PPAR gamma,” *Hypertension Research*, vol. 35, no. 7, pp. 715–719, 2012.

[178] T. Fang, Y. Di, G. Li et al., “Effects of telmisartan on TNFα induced PPAR© phosphorylation and insulin resistance in adipocytes,” *Biochemical and Biophysical Research Communications*, vol. 503, no. 4, pp. 3044–3049, 2018.

[179] K. Araki, T. Masaki, I. Katsuragi, K. Tanaka, T. Kakuma, and H. Yoshimatsu, “Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice,” *Hypertension*, vol. 48, no. 1, pp. 51–57, 2006.

[180] V. Kolli, L. A. Stechschulte, A. R. Dowling, S. Rahman, P. J. Czernik, and B. Lecka-Czernik, “Partial agonist, telmisartan, maintains PPAR© serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass,” *PloS One*, vol. 9, no. 5, article e96323, 2014.

[181] P. Shen, M. H. Liu, T. Y. Ng, Y. H. Chan, and E. L. Yong, “Differential effects of isoflavones, from *Astragalus membranaceus* and *Pueraria thomsonii*, on the activation of PPARα, PPARγ, and adipocyte differentiation in vitro,” *The Journal of Nutrition*, vol. 136, no. 4, pp. 899–905, 2006.

[182] T. Nie, S. Zhao, L. Mao et al., “The natural compound, formononetin, extracted from *Astragalus membranaceus* increases adipocyte thermogenesis by modulating PPAR© activity,” *British Journal of Pharmacology*, vol. 175, no. 9, pp. 1439–1450, 2018.
2012.

2007.

2006.

2015.

2015.

2005.

2013.

2014.

2015.

2009.

2011.

2014.

2008.

2012.

2016.

2018.

2019.

2016.

2015.

2017.

2018.

2011.

2006.

2013.

2015.

2012.

2014.

2015.

2017.

2015.

2011.

2005.

2015.

2014.

2016.

2014.

2010.

2014.
EPA at relative low concentrations by regulating PPARγ and its phosphorylation at Ser273 in 373-L1 adipocytes, "Nutrition & Metabolism," vol. 14, no. 1, p. 52, 2017.

[212] M. Thor, K. Beierlein, G. Dykes et al., "Synthesis and pharmacological evaluation of a new class of peroxisome proliferator-activated receptor modulators," Bioorganic & Medicinal Chemistry Letters, vol. 12, no. 24, pp. 3565–3567, 2002.

[213] C. Salim, Y. V. Boxberg, J. Alterio, S. Féréol, and F. Nothias, "The giant protein AHNAK involved in morphogenesis and laminin substrate adhesion of myelinating Schwann cells," Glia, vol. 57, no. 5, pp. 535–549, 2009.

[214] D. A. Yool, J. M. Edgar, P. Montague, and S. Malcolm, "The proteolipid protein gene and myelin disorders in man and animal models," Human Molecular Genetics, vol. 9, no. 6, pp. 987–992, 2000.

[215] L. Szalardy, D. Zadori, E. Tanczos et al., "Chronic myelinotoxicity and demyelination in animals and human tissues," FEBS Letters, vol. 585, no. 23, pp. 3821–3828, 2011.

[216] J. P. Taygerly, L. R. McGee, S. M. Rubenstein et al., "Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity," Bioorganic & Medicinal Chemistry, vol. 21, no. 4, pp. 979–992, 2013.

[217] K. A. Hanafy and J. A. Sloane, "Regulation of remyelination in multiple sclerosis," FEBS Letters, vol. 585, no. 23, pp. 131–134, 2013.

[218] F. L. Dunn, L. S. Higgins, J. Fredrickson, and A. M. DePalo, "Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes," Journal of Diabetes and its Complications, vol. 25, no. 3, pp. 151–158, 2011.

[219] A. Motani, Z. Wang, J. Weisssmann et al., "INT131: a selective modulator of PPARγ," Journal of Molecular Biology, vol. 386, no. 5, pp. 1301–1311, 2009.

[220] A. R. Roy, M. Jana, M. Kundu et al., "HMGC-CoA reductase inhibitors bind to PPARα to upregulate neurotrophin expression in the brain and improve memory in mice," Cell Metabolism, vol. 22, no. 2, pp. 253–265, 2015.

[221] D. A. Taha, C. H. De Moor, D. A. Barrett et al., "The role of acid-base imbalance in statin-induced myotoxicity," Translational Research, vol. 174, pp. 140–160.e14, 2016.

[222] A. V. Alvarez-Lueje, C. Valenzuela, J. A. Squella, and L. J. Núñez-Vergara, "Stability study of simvastatin under hydrolytic conditions assessed by liquid chromatography," Journal of AOAC International, vol. 88, no. 6, pp. 1631–1636, 2005.

[223] D. E. Vree, E. Dammers, I. Ulc, S. Horkovics-Kovats, M. Ryska, and I. J. Merkl, "Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers: gut hydrolysis of lovastatin is twice that of simvastatin," Tha Scientific World Journal, vol. 3, 1343 pages, 2003.

[224] D. E. Vree, E. Dammers, I. Ulc, S. Horkovics-Kovats, M. Ryska, and I. J. Merkl, "Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers: gut hydrolysis of lovastatin is twice that of simvastatin," The Scientific World Journal, vol. 3, 1343 pages, 2003.

[225] A. R. Roy, M. Jana, B. Ma et al., "In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s," Drug Metabolism and Disposition, vol. 25, no. 10, pp. 1191–1199, 1997.

[226] A. V. Alvarez-Lueje, C. Valenzuela, J. A. Squella, and L. J. Núñez-Vergara, "Stability study of simvastatin under hydrolytic conditions assessed by liquid chromatography," Journal of AOAC International, vol. 88, no. 6, pp. 1631–1636, 2005.

[227] T. B. Vree, E. Dammers, I. Ulc, S. Horkovics-Kovats, M. Ryska, and I. J. Merkl, "Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers: gut hydrolysis of lovastatin is twice that of simvastatin," The Scientific World Journal, vol. 3, 1343 pages, 2003.

[228] T. P. Trubekszaritont, L. M. Gorham, B. Ma et al., "In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s," Drug Metabolism and Disposition, vol. 25, no. 10, pp. 1191–1199, 1997.

[229] A. R. Roy, M. Jana, B. Ma et al., "In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s," Drug Metabolism and Disposition, vol. 25, no. 10, pp. 1191–1199, 1997.

[230] A. R. Roy, M. Jana, B. Ma et al., "In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s," Drug Metabolism and Disposition, vol. 25, no. 10, pp. 1191–1199, 1997.
[239] S. Fusco, C. Ripoli, M. V. Podda et al., “A role for neuronal CAMP responsive-element binding (CREB)-1 in brain responses to calorie restriction,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 2, pp. 621–626, 2012.

[240] T. Gu, “CST curation set: 2234, specificities of antibodies used to purify peptides prior to LCMS,” November 2019, https://www.phosphosite.org/curatedInfoAction.action?record=11076.

[241] D. E. Clark, C. E. Poteet-Smith, J. A. Smith, and D. A. Lanni-gan, “Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain,” *The EMBO Journal*, vol. 20, no. 13, pp. 3484–3494, 2001.

[242] B. G. Shearer, H. S. Patel, A. N. Billin et al., “Discovery of a novel class of PPARδ partial agonists,” *Bioorganic & Medicinal Chemistry Letters*, vol. 18, no. 18, pp. 5018–5022, 2008.

[243] S. Keil, H. Matter, K. Schönafinger et al., “Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxi-some proliferator-activated receptor (PPAR) γδ agonists with high potency and in vivo efficacy,” *ChemMedChem*, vol. 6, no. 4, pp. 633–653, 2011.

[244] T. Adhikary, K. Kaddatz, F. Finkernagel et al., “Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-βδ (PPARβδ),” *PLoS One*, vol. 6, no. 1, article e16344, 2011.

[245] F. A. H. Batista, D. B. B. Trivella, A. Bernardes et al., “Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding,” *PLoS One*, vol. 7, no. 5, article e33643, 2012.

[246] A. Ohtera, Y. Miyamae, K. Yoshida et al., “Identification of a new type of covalent PPARγ agonist using a ligand-linking strategy,” *ACS Chemical Biology*, vol. 10, no. 12, pp. 2794–2804, 2015.

[247] I. M. Serafinova, M. A. Pufall, S. Krishnan et al., “Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles,” *Nature Chemical Biology*, vol. 8, no. 5, pp. 471–476, 2012.

[248] R. M. Miller, V. O. Paavilainen, S. Krishnan, I. M. Serafinova, and J. Taunton, “Electrophilic fragment-based design of reversible covalent kinase inhibitors,” *Journal of the American Chemical Society*, vol. 135, no. 14, pp. 5298–5301, 2013.

[249] C. F. H. Allen and W. J. Humphlett, “The thermal reversibility of the Michael reaction: V. the effect of the structure of certain thiol adducts on cleavage,” *Canadian Journal of Chemistry*, vol. 44, no. 19, pp. 2315–2321, 1966.

[250] H. Kim, A. Jo, S. S. Choi et al., “Rational design and synthesis of reversible covalent PPARγ antagonistic ligands inhibiting Ser273 phosphorylation,” *Asian Journal of Organic Chemistry*, vol. 8, no. 9, pp. 1698–1706, 2019.

[251] J. Y. Jang, H. Kim, H.-J. Kim, S. W. Suh, S. B. Park, and B. W. Han, “Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation,” *Scientific Reports*, vol. 9, no. 1, article 11168, 2019.

[252] P. S. Palkar, M. G. Borland, S. Naruhn et al., “Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-βδ antagonist GSK3787,” *Molecular Pharmacology*, vol. 78, no. 3, pp. 419–430, 2010.